- Home
- LEXX vs COEP Comparison
LEXX vs COEP Comparison
Compare LEXX & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- COEP
- Stock Information
- Founded
- LEXX 2004
- COEP 2017
- Country
- LEXX Canada
- COEP United States
- Employees
- LEXX N/A
- COEP N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEXX Health Care
- COEP Health Care
- Exchange
- LEXX Nasdaq
- COEP Nasdaq
- Market Cap
- LEXX 39.1M
- COEP 32.4M
- IPO Year
- LEXX N/A
- COEP N/A
- Fundamental
- Price
- LEXX $1.45
- COEP $10.52
- Analyst Decision
- LEXX Strong Buy
- COEP
- Analyst Count
- LEXX 2
- COEP 0
- Target Price
- LEXX $9.50
- COEP N/A
- AVG Volume (30 Days)
- LEXX 110.6K
- COEP 109.2K
- Earning Date
- LEXX 04-08-2025
- COEP 03-25-2025
- Dividend Yield
- LEXX N/A
- COEP N/A
- EPS Growth
- LEXX N/A
- COEP N/A
- EPS
- LEXX N/A
- COEP N/A
- Revenue
- LEXX $496,923.00
- COEP N/A
- Revenue This Year
- LEXX $30.72
- COEP N/A
- Revenue Next Year
- LEXX $31.85
- COEP N/A
- P/E Ratio
- LEXX N/A
- COEP N/A
- Revenue Growth
- LEXX 77.63
- COEP N/A
- 52 Week Low
- LEXX $1.38
- COEP $2.31
- 52 Week High
- LEXX $6.85
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- LEXX 33.85
- COEP 48.65
- Support Level
- LEXX $1.38
- COEP $9.27
- Resistance Level
- LEXX $1.72
- COEP $12.95
- Average True Range (ATR)
- LEXX 0.12
- COEP 1.59
- MACD
- LEXX -0.01
- COEP -0.33
- Stochastic Oscillator
- LEXX 12.85
- COEP 38.56
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.